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Background: Multiple factors likely impact response and remission rates in the treat-
ment of depression with repetitive transcranial magnetic stimulation (rTMS). Notably, the 
role of symptom severity in outcomes with rTMS is poorly understood.
Objective/hypothesis: This study investigated the predictors of achieving remission in 
patients suffering from depression who receive ≥3 rTMS treatments per week.
Methods: Available data on 41 patients treated at Walter Reed National Military 
Medical Center from 2009 to 2014 were included for analysis. Patients received a range 
of pulse sequences from 3,000 to 5,000 with left-sided or bilateral coil placement. 
Primary outcome measures were total score on the Patient Health Questionnaire-9 
or the Quick Inventory of Depressive Symptomatology-Self Rated. Remission was 
defined as a total score less than five, and response was defined as a 50% decrease 
in the total score on both outcome metrics. Outcomes in patients diagnosed as 
suffering from mild or moderate depression were compared to those suffering from 
severe depression.
results: Of the 41 patients receiving treatment, 16 reached remission and 18 reached 
response by the end of treatment. Remission rate was associated with the initial severity 
of depression, with patients with mild or moderate depression reaching remission at 
a significantly higher rate than those with severe depression. Total number of rTMS 
sessions or length of treatment was not predictors of remission.
conclusion: Patients with a baseline level of depression characterized as mild or mod-
erate had significantly better outcomes following rTMS compared to patients with severe 
depression.
Keywords: rTMs, depression, frequency, remission, response
Abbreviations: PDMS, patient data management system; PHQ, patient health questionnaire; QIDS-SR, quick inventory of 
depressive symptomatology; rTMS, repetitive transcranial magnetic stimulation.
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introduction
In October 2008, the U.S. Food and Drug Administration (FDA) 
cleared the use of repetitive transcranial magnetic stimulation 
(rTMS) for the acute treatment of major depression. Studies cited 
in support of this decision used the Neuronetics Neurostar TMS 
Therapy® system with an iron core figure-8 coil at 10  pulses/s, 
120% of the motor threshold (MT), 3,000 pulses per treatment, 
and five treatments per week for 4–6  weeks (1–3). Since FDA 
approval, several subsequent studies have supported the findings 
of efficacy of rTMS in treating depression. In a non-industry 
supported study, George et al. (4) reported similar findings that 
further substantiate the use of rTMS for treatment of depression 
(4). A meta-analysis of 18 good or fair quality studies investigating 
the use of rTMS for treatment-resistant depression reported that 
rTMS is a reasonable, effective consideration (5). The preponder-
ance of evidence would therefore appear to suggest a beneficial 
effect of rTMS as a treatment for depression.
To most effectively apply rTMS treatment for depression, 
extensive research efforts have investigated possible predictors of 
outcome. Age of the patient and medication refractoriness are 
two key indicators for response to rTMS treatment, with younger 
and non-refractory patients responding better to treatment (3, 6). 
In fact, treatment resistance is a consistently reported predictor 
of antidepressant response (7–9). Fregni et al. (6) speculated that 
individuals refractory to pharmacological or other therapies may 
have a more severe form of depression, which would explain why 
those individuals have a reduced response to therapy (6). In a 
limited-scale study, Su et al. (10) reported that patients with less 
severe depression have a greater response to rTMS treatment 
(10). In contrast to those results, Lisanby et al. (3) determined 
that baseline symptom severity had no impact on treatment 
outcome (3). Numerous other factors have also been suggested 
as predictors for outcome, including depressive subtype (11), 
anxiety comorbidity (12, 13), duration of the current depressive 
episode, and polymorphisms affecting serotonin and glutamate 
transmission (14, 15).
To answer questions regarding outcome predictors of remis-
sion following rTMS treatment, we conducted a retrospective 
study of patients treated for depression at Walter Reed National 
Military Medical Center (WRNMMC). Parameters examined 
included baseline depression levels, total number of sessions, 
length of treatments, and pulse frequencies.
Materials and Methods
We included all patients (N = 70) previously treated for depres-
sion with rTMS at WRNMMC between March 2009 and February 
2014 whose data were retained within the patient data manage-
ment system (PDMS). The population consisted of both females 
(57.5%) and males (42.5%) with a mean age of 41.0 (SD = 15.5) 
(Table 1). Variations of treatment delivery occurred due to pro-
vider and patient preference. Compliance, and therefore inclu-
sion in this study, was determined to be ≥3 treatments per week.
Forty-six of the 70 participants maintained the compliance 
standard of three or more treatments per week (66% compli-
ance), while 5 participants were missing outcome data and were 
removed from the analysis. Therefore, data from 41 patients were 
included in this study  –  20 individuals with mild-to-moderate 
depression and 21 individuals with severe depression (Figure 1). 
The current study was performed following review and approval 
by the WRNMMC Institutional Review Board. The study was 
conducted in accordance with all Federal laws, regulations, 
and standards of practice as well as those of the Department of 
Defense and the Departments of Army/Navy/Air Force.
Prior to beginning rTMS administration, providers adminis-
tered the Patient Health Questionnaire-9 (PHQ-9) (16) and/or 
the Quick Inventory of Depressive Symptomatology-Self Rated 
(QIDS-SR) (17). All patients were treated with NeuroStar TMS 
Therapy® by Neuronetics. For this study, administration consisted 
of at least 10 treatment sessions. A 50% decrease in the patients 
PHQ-9 or QIDS-SR score from baseline defined “response.” 
A score of <5 for the QIDS-SR and <5 for the PHQ-9 defined 
remission.
The NeuroStar® device includes a PDMS, which is a self-
contained HIPAA-compliant electronic health record. The 
PDMS is able to store demographic data, dates and parameters 
of treatment, and scores from rating scales administered during 
treatment. The following patients were excluded from the study: 
received <10 treatments, no PHQ-9 or QIDS-SR scores, did not 
meet the minimal depression criteria for the PHQ-9 (five or 
greater) or QIDS-SR (six or greater), or did not receive left-sided 
or bilateral coil placement. Left-sided treatments were adminis-
tered at 10 Hz, 120% of the MT, 3,000–5,000 pulses per treatment, 
in 4-s stimulus trains with 26 s rest intervals. Bilateral treatments 
were administered initially left-sided at 10 Hz, 120% of the MT, 
3,500 pulses, in 4-s stimulus trains with 26  s rest intervals fol-
lowed by right-sided application of 1 Hz, 120% of the MT, 1,500 
pulses, in 26-s stimulus trains with 4-s rest intervals. All stimuli 
were applied 5.5 cm anterior of the MT location corresponding to 
the abductor pollicis brevis. Data were extracted from the PDMS, 
de-identified, and entered into an Excel sheet. We extracted all 
rating scales scores, the frequency of treatment, the number of 
pulses per treatment, the dates of treatment, and the coil place-
ments during treatment.
Binary logistic regression (backward Wald) was utilized 
to determine whether the number of session, length of treat-
ments (weeks), pulse frequency or baseline depression scores 
predicted remission (final outcome score <5) using rTMS. A 
TaBle 1 | Overall demographic information on all patients included in 
the retrospective study investigating the use of rTMs as a treatment for 
depression following mTBi (n = 41).
Age, M(SD) 41.0 (±15.5)
Gendera % of sample
 Male 17/40 (42.5%)
 Female 23/40 (57.5%)
Number of sessions, M(SD) 26.0 (±7.4)
Frequency
 3,000 L 66.7%
 5,000 L 2.4%
 3,500 L and 1,500 R 9.5%
 Mixed 21.4%
aThe gender data from one individual was missing. Therefore, percentages are based 
off of an n = 40.
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FigUre 2 | remission rates were significantly higher in participants with mild-to-moderate depression than in those individuals initially diagnosed 
as experiencing severe depression. *Denotes a significant difference of p = .007; mild-moderate, n = 20; severe, n = 21.
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Chi-squared (χ2) test was run to determine differences in depres-
sion severity scores (mild-to-moderate versus severe) for remis-
sion. Severity was classified by either PHQ-9 or QIDS-SR scale 
cutoffs as described in Figure 1.
results
Across all severity levels of depression, 16 of the 41 (38%) 
patients reached remission by the end of their treatment. In the 
mild-to-moderate group, 12 of the 20 (60%) achieved remission; 
in the severe group, 4 of the 21 (19%) achieved remission. Across 
all severity levels of depression, response rate was reached by 18 
of the 41 (43.9%) patients. In the mild-to-moderate group, 11 
of the 20 (55%) achieved response; in the severe group, 7 of the 
21 (33%) achieved response. Baseline depression severity scores 
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FigUre 1 | Mean score at admission and discharge for the combined depression metrics. Mild ≤ 10; Moderate (Mod.) = 11–15; Severe ≥ 16. n = 41.
were the only significant predictor of improvement following 
rTMS treatment (p  =  .008). Patients with mild-to-moderate 
depression had a significantly greater rate of remission than 
patients with severe depression [χ2(1) = 7.22, p =.007, Figure 2]. 
Patients with mild-to-moderate depression improved on aver-
age by 6.25  U (49.41% of the initial score) on the outcome 
measures, and patients with severe depression improved on 
average by 7.90 U (41.06% of the initial score) on the outcome 
measures. Further, these data suggest an inverse relationship 
between baseline symptom severity and the likelihood of reach-
ing remission from rTMS treatment. For each unit, decrease in 
baseline severity scores, the odds of remission (OR) increase by 
36% (OR = 1.36). Total number of sessions, length of treatments 
(weeks), and unilateral or bilateral treatment delivery were not 
significant predictors of remission.
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Discussion
Initial severity of depression was the only predictor of reach-
ing remission, with patients suffering from mild-to-moderate 
depression being most likely to remit. Rates of remission may be 
a consequence of the extent of improvement needed to obtain a 
PHQ-9 or QIDS-SR score of <5. This suggests a fixed magnitude 
of improvement on validated rating scales regardless of the 
 severity of depression, resulting in differences with overall rates of 
remission. Though limited by a small sample size, of interest is the 
determination that the total number of sessions, length of treat-
ments (weeks), and laterality of treatment were not significant 
predictors of achieving remission.
Numerous studies have reported possible predictors for 
outcome following rTMS treatment of depression. These pre-
dictors include factors, such as anxiety comorbidity, depressive 
subtype, and duration of the current episode. This study shows 
a relationship between the severity of the depression and the 
likelihood of a positive outcome following rTMS treatment. 
In a limited-scale study, Su et al. (10) reported similar results; 
however, those researchers studied a patient population that was 
primarily female (10). Both Su et al. (10) and the current study 
described above are in contrast to the results reported by Lisanby 
et al. (3). It should be noted, however, that Lisanby reported only 
the depression severity for the total sample, without providing 
a more detailed breakdown of the depression scores and the 
specific responses to treatment as affected by depression sever-
ity. Therefore, it is difficult to explain differences between the 
three studies.
A growing body of research investigating responses to rTMS 
treatment suggests underlying physiological characteristics of 
depression may be the primary predictors of remission. Further 
research should help clarify which patients may respond best to 
rTMS and assist with targeted patient selection.
This study had several limitations. This was a limited-scale 
retrospective study, and the numbers of patients were unequally 
distributed among mild, moderate, and severe categories. Patients 
were not distinguished beyond suffering from depression versus 
major depressive disorder, which may lead to population bias 
when considering severity. This was a retrospective study analyz-
ing data from a clinical setting, so the application and consistency 
of treatments were perhaps not as rigorously applied as in a more 
controlled clinical trial. The data set did not include several clini-
cal factors, such as comorbidity, duration of illness, concomittant 
medication, types of prior treatments and degree of treatment 
resistance. Without the ability to consider these other variables, 
the results showing correlation to severity of depression could be 
a Type I error.
This study provides evidence that the severity of depression at 
the onset of treatment with rTMS may be one factor in achiev-
ing remission. Further, the total number of sessions, length 
of treatments (weeks), and laterality of treatment were not 
significant predictors of remission.
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